<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03951207</url>
  </required_header>
  <id_info>
    <org_study_id>YMC040</org_study_id>
    <nct_id>NCT03951207</nct_id>
  </id_info>
  <brief_title>Rosuvastatin/Amlodipine vs Atorvastatin/Amlodipine in Hypertension Patient With Dyslipidemia</brief_title>
  <acronym>CORONA</acronym>
  <official_title>Randomized, Multicenter, Parallel, Open, Phase 4 Study to Compare the Efficacy and Safety of Rosuvastatin/Amlodipine Combination Therapy Versus Atorvastatin/Amlodipine Combination Therapy in Hypertension Patient With Dyslipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuhan Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yuhan Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to Compare the Efficacy and Safety of Rosuvastatin/Amlodipine Combination
      Therapy Versus Atorvastatin/Amlodipine Combination Therapy in Hypertension patient with
      Dyslipidemia
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 2, 2019</start_date>
  <completion_date type="Anticipated">February 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of change from baseline to week 8 in LDL-Cholesterol</measure>
    <time_frame>Baseline/Week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of change from baseline to week 4 in LDL-Cholesterol</measure>
    <time_frame>Baseline/Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who reached the therapeutic goal to week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>* Group I: &lt; 160 mg/dL, Group II: &lt; 130 mg/dL, Group III: &lt; 100 mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change from baseline to week 4, 8 in lipid profile(without LDL-C)</measure>
    <time_frame>Baseline/Week 4, 8</time_frame>
    <description>Total cholesterol, HDL-C, Triglyceride, Apo A-1, Apo B, Apo B/Apo A-1, Lipoprotein(a)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change from baseline to week 4, 8 in hs-CRP</measure>
    <time_frame>Baseline/Week 4, 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change from baseline to week 4, 8 in glucose index</measure>
    <time_frame>Baseline/Week 4, 8</time_frame>
    <description>Fasting Blood Glucose, HbA1C, HOMA-IR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change from baseline to week 4, 8 in msSBP &amp; msDBP in both arm</measure>
    <time_frame>Baseline/Week 4, 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change from baseline to week 4, 8 in difference of msSBP &amp; msDBP in both arm</measure>
    <time_frame>Baseline/Week 4, 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of major adverse cardiovascular and cerebrovascular events (MACCE)</measure>
    <time_frame>Week 8</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">324</enrollment>
  <condition>Dyslipidemias</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Rosuampin 10/5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rosuvastatin 10mg/Amlodipine 5mg qd for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rosuampin 20/5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rosuvastatin 20mg/Amlodipine 5mg qd for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amlodipine/Atorvastatin 5/20mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atorvastatin 20mg/Amlodipine 5mg qd for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuampin 10/5mg</intervention_name>
    <description>Rosuvastatin 10mg/Amlodipine 5mg qd for 8 weeks</description>
    <arm_group_label>Rosuampin 10/5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuampin 20/5mg</intervention_name>
    <description>Rosuampin 20/5mg qd for 8 weeks</description>
    <arm_group_label>Rosuampin 20/5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine/Atorvastatin 5/20mg</intervention_name>
    <description>Amlodipine/Atorvastatin 5/20mg qd for 8 weeks</description>
    <arm_group_label>Amlodipine/Atorvastatin 5/20mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Both man and woman who is over 19 years old

          -  Patient with dyslipidemia and hypertension

          -  Written informed consent

        Exclusion Criteria:

          -  Triglyceride ≥ 400 mg/dL at screening

          -  Hypertensive patients who need antihypertensive medication except Amlodipine,
             β-blockers, RAS inhibitors

          -  sSBP difference is ≥20 mmHg or sDBP difference is ≥10 mmHg

          -  A history of rhabdomyolysis, myopathy

          -  Patient with hypersensitivity to Statin or Amlodipine

          -  Patients undergoing eGFR &lt;30 mL/min/1.73 m2 (MDRD) at screening

          -  AST(Aspartate Aminotransferase) or ALT(Alanine Aminotransferase) level ≥ 3x ULN (upper
             limit of normal range) or active liver disease

          -  Creatine kinase (CK) level ≥ 5x ULN (upper limit of normal range)

          -  Contraindications stated in the Label of Rosuampin or Caduet

          -  Those participating in other clinical trials for investigational products at screening

          -  Patients deemed to be ineligible to participate in the trial by investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Daegu Catholic Univ. Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MalSoon Park</last_name>
      <phone>+82-53-650-4344</phone>
      <email>joonmom77@naver.com</email>
    </contact>
    <investigator>
      <last_name>Kee-Sik Kim, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 13, 2019</study_first_submitted>
  <study_first_submitted_qc>May 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2019</study_first_posted>
  <last_update_submitted>July 2, 2019</last_update_submitted>
  <last_update_submitted_qc>July 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Amlodipine, atorvastatin drug combination</mesh_term>
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

